Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Good points to reinforce.

Leo has brought Brilacidin to the point where the pharmaceutical companies should be able to project an assessment of value as well an estimate of the degree of risk. I think it is safe to say negotiations for licensing and partnership are underway.

From the audio of the biotechnology conference IPIX summary
I summarized Leo's statements in post 213096:

Last 1 to 1.5 years what we have done is to broaden our drug candidates to a value inflection...Brillacidin anchored with Oral mucositis ...also[potential for] IBD...skin structures...Kevetrin... and Prurisol

Over this year talking to a lot of people not only here but at other get togethers...trying to leverage all of this with partnering opportunities...

From his statements Leo seems to be confident he is at a good point to negotiate a fair value for Brilacidin, at least and perhaps for more.

http://www.ipharminc.com/press-release/2018/1/16/innovation-pharmaceuticals-presents-at-2018-biotech-conference-oral-mucositis-drug-candidate-garners-exceptional-interest-after-successful

“What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”


"We've reached that point for B. In the next two months we'll reach that point for P and K, too. This is an exciting time. Hopefully lucrative too."